We provide initial insights into two critical issues: what clinical
value can be extracted from different
commercial and academic cancer genomic
platforms, and how to think about scaling access to that
value,» noted the study's Principal Investigator, Robert Darnell, MD, PhD, Robert and Harriet Heilbrunn Professor and Senior Attending Physician at The Rockefeller University and Founding Director
of the New York Genome Center.